U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H25N
Molecular Weight 255.3978
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIMEMORFAN

SMILES

[H][C@]12CCCC[C@]13CCN(C)[C@H]2CC4=CC=C(C)C=C34

InChI

InChIKey=KBEZZLAAKIIPFK-NJAFHUGGSA-N
InChI=1S/C18H25N/c1-13-6-7-14-12-17-15-5-3-4-8-18(15,16(14)11-13)9-10-19(17)2/h6-7,11,15,17H,3-5,8-10,12H2,1-2H3/t15-,17+,18+/m1/s1

HIDE SMILES / InChI
Molecular Formula C18H25N
Molecular Weight 255.3978
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dimemorfan is a nonnarcotic antitussive drug. The antitussive action of dimemorfan appears to be directly on the cough center in the medulla.

CNS Activity

CNS Active
3913
Curator's Comment: Dimemorfan exhibits an anticonvulsant effect.

Originator

Yamanouchi Pharmaceutical
31
Curator's Comment: Yamanouchi Pharmaceutical now is a part of Astellas Pharma.

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
ASTOMIN

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of the centrally acting antitussives on ascites tumor cells.
1983 Apr
The nonnarcotic antitussive drug dimemorfan: a review.
1997 Mar-Apr
Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice.
2004 May 5
Pharmacology and therapeutic potential of sigma(1) receptor ligands.
2008 Dec
Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation.
2008 Jan
The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes.
2010 Feb
Patents

Patents

JP2001097856A
2
JP2001151677A
2
JP2005289904A
2
JP2005289905A
2
JP2005289906A
2
JPH1072349A
2

Sample Use Guides

In Vivo Use Guide
20 mg three times daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:05:56 GMT 2023
Edited
by admin
on Fri Dec 15 16:05:56 GMT 2023
Record UNII
623OAC38YU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIMEMORFAN
INN   MI   WHO-DD  
INN  
Official Name English
DIMEMORFAN [MI]
Common Name English
dimemorfan [INN]
Common Name English
Dimemorfan [WHO-DD]
Common Name English
(+)-3,17-DIMETHYLMORPHINAN
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C66917
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
WHO-VATC QR05DA11
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
WHO-ATC R05DA11
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
NCI_THESAURUS C264
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
Code System Code Type Description
MESH
C012621
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
WIKIPEDIA
Dimemorfan
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
ChEMBL
CHEMBL2106325
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
MERCK INDEX
m4499
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY Merck Index
EVMPD
SUB07158MIG
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
SMS_ID
100000082655
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
DRUG BANK
DB13810
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
CAS
36309-01-0
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
FDA UNII
623OAC38YU
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
PUBCHEM
3037918
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID301043335
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
NCI_THESAURUS
C65399
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
INN
3497
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
DRUG CENTRAL
900
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
ECHA (EC/EINECS)
252-963-3
Created by admin on Fri Dec 15 16:05:56 GMT 2023 , Edited by admin on Fri Dec 15 16:05:56 GMT 2023
PRIMARY
Related Record Type Details
Structure of DIMEMORFAN PHOSPHATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of DIMEMORFAN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966